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Abstract
The importance of the Piwi-interacting RNA (piRNA) pathway for germ cell maintenance, genome integrity, DNA
methylation and retrotransposon control raises possible roles of this pathway in cancer. Indeed aberrant expression of
human PIWI orthologs and Maelstrom has been observed in various cancers. In this study we explored the expression and
function of piRNA pathway genes in human ovarian cancer, based on our recent work, which showed widespread
expression of piRNA pathway genes in the mammalian. Our work shows that PIWIL1 and MAEL expression is significantly
increased in malignant EOC (n = 25) compared to benign tumor tissues (n = 19) and normal ovarian tissue (n = 8). The
expression of PIWIL3 is lower in malignant and benign tissues when compared to normal ovary. Sequencing of PIWIL1
transcript revealed that in many tumors deletion of exon 17 leads to the introduction of a premature stop codon in the PIWI
domain, likely due to a splicing error. In situ hybridization on tumor sections revealed that L1, PIWIL1, 2 and MAEL are
specifically expressed in epithelial cells (cancerous cells) of EOC. Furthermore, PIWIL2 and MAEL are co-expressed in the
stromal cells adjacent to tumor cells. Since PIWIL1 and MAEL are up regulated in malignant EOC and expressed in the
epithelial cells, we investigated if these two genes affect invasiveness of ovarian cancer cell lines that do not normally
express these genes. PIWIL1 and MAEL were transiently over expressed in the ovarian cancer cell line SKOV3, followed by
real-time measurements of cell invasiveness. Surprisingly both PIWIL1 and MAEL over expression decreased the invasiveness
of SKOV3 cells. Our findings support a growing body of evidence that shows that genes in this pathway are upregulated in
cancer. In ovarian cancer we show for the first time that Piwil1 transcript may often be abnormal result in non functional
product. In contrast to what has been observed in other cell types, we found that PIWIL1 and MAEL have a repressive effect
on cell invasiveness.
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Introduction
Ovarian cancer is the most lethal gynaecological cancer, and
the fifth leading cause of cancer-related death among women in
the Western World [1]. The five-year relative survival rate for
women with ovarian cancer is only around 40% [1]. Ovarian
cancers are heterogeneous tumors which exhibit distinct morpho-
logical characteristics, genetic mutations and origins. There are
three major types of ovarian cancer - epithelial, germ cell and sex
cord stromal tumors. Ovarian germ cell tumors and sex cord
stromal tumors comprise 10% of ovarian cancers, and are derived
from primitive ovarian germ cells or mesenchymal cells in the sex-
cord derived tissue of the ovary, respectively [2]. EOCs account
for more than 90% of ovarian malignancies. Based on histology
EOCs are classified into four main subtypes (serous, mucinous,
endometroid and clear cell carcinomas) with over 70% of the cases
diagnosed as serous carcinomas (SCs) [3].
Alterations of the epigenetic landscape such as global DNA
hypomethylation and gene specific DNA hypermethylation are
frequently reported in cancer cells [4]. Global DNA hypomethyla-
tion largely affects the intergenic and intronic regions of the
genome, especially repeat sequences and transposable elements
(TEs), which account for about 55% of the human genome [5],
including 17% L1 repeats [6]. In somatic cells, DNA methylation
of TEs is crucial to prevent their expression which can jeopardise
integrity of the genome. During germ cell development, there is a
transient period of global DNA hypomethylation which results in
temporary activation of TEs [7].
The piRNA pathway is evolutionarily highly conserved in
metazoa and consists of 21–26 nt piRNAs which bind PIWI
proteins to mediate posttranslational control of TE expression and
play a role in epigenetic changes (such as DNA methylation) via
interaction with other proteins (such as MAEL or HP1) [8,9]. In
mammals there are several Piwi like (Piwil) genes (three in mice,
four in humans). Expression of Piwil genes and piRNA pathway
associated genes has been demonstrated at various stages of germ
cell development in particular in testis. Piwil1 (Miwi) has previously
been identified as a gene exclusively expressed in mouse testis and
essential for spermatogenesis [10]. More recently expression of
Piwil1 has also been demonstrated in mouse and human ovary
[11]. Mutation of Piwil2, Piwil4 and Mael in mouse leads to similar
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phenotypes including elimination of TE DNA methylation and
male sterility [8]. There is now growing evidence of piRNA
activity also in the mammalian ovary, however knock out
experiments of piRNA pathway gene in mice so far has only led
to male sterility [12–14].
There is mounting evidence of piRNA pathway activity in
various cancers. Expression of PIWIL1 and PIWIL2 has been
found in a wide range of human cancers such as stomach, breast,
gastrointestinal tract and endometrium [15–18] and recently also
in ovarian carcinoma [19]. Increased expression of PIWIL1 is
associated with enhanced tumor growth [20] increased tumor
grades [21], poor diagnostic outcomes [22] and mortality [23].
PIWIL2 is widely expressed in early-stage breast and cervical
cancers and pre-cancerous stem cells involved in tumorigenesis
[18]. The expression pattern of PIWIL3 and 4 has only been
studied in colon cancers [24]. Maelstrom (MAEL) is a known testis
cancer gene [25].
Our finding of expression in ovarian somatic cells [11] together
with decreased DNA methylation at L1 promoter region
associated with the progression of cervical and uterus cancers
[26] and poor prognosis in ovarian carcinomas [27] led us to
investigate whether piRNA pathway genes could play a role in
EOCs. In this study, we investigated the expression of PIWIL1–4
and MAEL in 25 EOC, 19 benign tumor samples, and 8 normal
ovarian tissues. We found significantly elevated expression of
PIWIL1 and MAEL in EOC compared to benign and normal
ovarian tissues. However, PIWIL1 transcripts in EOC may not be
functional due to deletions identified in the PIWI domain of this
transcript. Furthermore, overexpression of PIWIL1 and MAEL




Total RNAs from human testis and pre-menopause ovarian
tissues were purchased from Stratagene (USA). Malignant, benign
and normal ovarian tissues (Table 1 and Table S3) were collected
with informed written consent of the patient and approval by the
Ethics Committee of the Royal Adelaide Hospital, Adelaide,
South Australia.
Cell lines
Human ovarian cancer cell lines SKOV3 and OVCAR3 were
purchased from American Type Culture Collection (ATCC, USA)
while OVCAR5 was obtained from Dr. Thomas Hamilton (Fox
Chase Cancer Center, Philadelphia, PA) Johnson et al Cancer Res
57: 850–856 1997. Cell lines were maintained in RPMI 1640
medium supplemented with L-glutamine (2 mM), Penicillin-
streptomycin (100 U/ml, 100mg/ml) (Sigma). SKOV3 and
OVCAR3 cells were supplemented with 5% FBS (Invitrogen)
whilst OVCAR5 cells were supplemented with 10% FBS and
7.5 mg/ml insulin. All cell lines were maintained at 37uC in a
humid chamber with 5% CO2.
RNA isolation and cDNA synthesis
RNA was isolated from tissues and cell lines using TRIzol
reagent (Invitrogen) following the manufacturer’s instructions.
RNA was resuspended in nuclease free water, and stored at -80uC.
RNA was treated with DNase I (New England Biolabs) before
reverse transcription. 1mg of RNA was used to obtain cDNA using
the Super Script III First-strand Synthesis System (Invitrogen)
following the manufacturer’s protocol. Briefly, RNA was incubat-
ed with 1ml of 50 mM oligo(dT)20 and 1ml of 10 mM dNTPs for 10
mins at 65uC. After incubation, 4ml of 5x RT buffer, 2ml of
dithiothreitol (DTT, 0.1 M), 1ml of RNaseOUT (40 U/ml) and 1ml
of Super Script III RT enzyme (200 U/ml) were added and
incubated for 50 mins at 50uC. The reaction was terminated at
85uC for 5 mins. cDNAs were stored at 220uC.
Gene expression analyses
RT-PCR was performed to determine the level of mRNA for
the five piRNA pathway genes (Table S1) and beta actin (ACTB) in
52 patient samples and 3 ovarian cancer cell lines. Each 25ml
reaction contained 200 ng of cDNA, 5ml of 5x Go Taq Green
Master Mix (Promega), 1ml of 5 mM dNTP solution (Roche), 0.5ml
of each primer (20 pmol/ml) and 0.5ml Taq DNA polymerase. The
PCR conditions were the same for all genes, except the annealing
temperature (Table S1), and were as follows: initial denaturation at
95uC for 2 mins, 95uC for 30 secs, annealing at gene specific
temperature for 30 secs (Table S1), extension at 72 uC for 1 min,
32 cycles. PCR of ACTB control was performed with 27 cycles,
followed by 5 mins of final extension at 72 uC. The PCR products
were visualized on a 1.5% agarose gel stained with ethidium
bromide. Band intensity was measured (Quantity One program,
Version 4, Bio-Rad), and the relative intensity of each gene was
normalized to that of ACTB. PCR products were confirmed by
sequencing (Big Dye Terminator v3.1 cycle sequencing kit,
Applied Biosystems). RT–PCR was performed in triplicate for
each primer pair.
Statistical analyses of gene expression
Data are presented as median relative expression (first quartile
to third quartile). The transcript level of each gene was normalized
against ACTB. Kolmogorov-Smirnov and Shapiro-Wilk tests
suggested that the expression level of each gene from all of the
52 samples is not normally distributed. Thus, a Kruskal-Wallis test,
which uses a non-parametric method, was used to compare the
gene expression from malignant, benign and normal groups. The
Spearman’s correlation test was performed to investigate the
correlation between a patient’s age and consequent gene
expression. R-value closer to 1 indicates a stronger positive
correlation, whereas an R-value closer to -1 shows a stronger
negative correlation. In the Kruskal-Wallis and Spearman’s tests, a
P-value of ,0.05 was considered statistically significant.
Table 1. Age and cancer stage of EOC, benign tumors and normal ovaries.
Tissue n Median of patient age in years (range) Cancer stage
Serous carcinomas 25 60 (37–75) See Table S3
Benign ovarian lesions 19 60 (36–88) -
Normal ovaries 8 48 (44–76) -
doi:10.1371/journal.pone.0099687.t001
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RNA in situ hybridization
Probes were labelled with digoxigenin-11-UTP (Roche Diag-
nostics) according to the manufacturer’s protocol. Formalin-fixed
paraffin-embedded tissue sections were deparaffinised in xylene
and subsequently washed in graded ethanol. All solutions were
prepared in diethylpyrocarbonate (DEPC)-treated H2O to inacti-
vate RNase activity. mRNA-bound nucleoproteins were removed
by proteinase K incubation (1.2mg/ml) (Roche Diagnostics) for
30 mins at 37 uC. Slides were washed with 1x PBS and acetylated
(1 M triethanolamin/0.178% HCl/0.25% acetic anhydride).
Slides were prehybridised at 65uC for 2 hrs with prehybridization
buffer (50% deionized formamide/2x SSC/1x Denhardt’s solu-
tion/0.005 M phosphate buffer/10% dextran sulphate/1 mg/ml
yeast total RNA/1 mg/ml salmon sperm DNA) and hybridised
with about 200 ng of cRNA probe in prehybridization buffer
overnight at 50uC in a humid chamber. Slides were washed in 2x
SSC, 1x SSC, 0.5x SSC and 0.1x SSC for 15 mins each at 50uC.
To remove unbound cRNA probes, the tissue was subjected to
RNase A (150mg/ml) digestion for 30 mins at 37uC. Specifically
bound cRNA probes were detected using an anti-DIG antibody
coupled to alkaline phosphatase with nitrobluetetrazolium chlo-
ride/X-phosphate-5-bromo-4-chloro-3-indolylphosphate (NBT/
BCIP) (Roche Diagnostics) as chromogenic substrate.
Cloning and construct preparation for invasion analyses
The MAEL (CCDS1257) and PIWIL1 (CCDS9268) cDNA
sequences were obtained from the NCBI CCDS database. Full-
length cDNA sequence was amplified using the Expand High
Fidelity PCR system (Roche) according to the manufacturer’s
protocol and cloned into a pcDNA3.1 mammalian expression
vector. Plasmid DNAs including pcDNA 3.1 (Invitrogen) or
pEGFP-N1 empty vectors (Clontech) were transfected into
SKOV3 cells using Lipofectamine LTX (Invitrogen) following
the manufacturer’s instruction. SKOV3 cells were selected due to
their endogenous L1 expression levels and the fact that they
showed no piRNA pathway gene expression (Fig. 1C). For each
transfection, 86104 SKOV3 cells were seeded onto a 24-well plate
14 hrs before transfection and were cultured in RPMI 1640/5%
FBS without Penicillin-streptomycin. Plasmid DNA (500 ng) was
diluted in 100ml of Opti-MEM medium (Invitrogen) and incubated
with 0.5ml Plus reagent (Invitrogen) and 2ml Lipofectamine LTX
(Invitrogen) for 30 mins before being added into each well. After
6 hrs, the cell culture medium was replaced with new RPMI
1640/5% FBS medium and cells were incubated for 24 hrs at
37uC, 5% CO2 before harvesting for in vitro invasion analyses. The
transfection of pEGFP-N1 empty vectors into SKOV3 cells
allowed the transfection efficiency to be measured, as successfully
transfected cells expressed the GFP protein. The pEGFP-N1
vector was subjected to the same growth and transfection
conditions as outlined above, to determine the transfection
efficiency which was approximately 70% after 24 hrs.
In vitro invasion analyses with xCelligence
Cell invasion was tested with real-time invasion assay monitor-
ing using CIM devices and the xCelligence DP system (Roche
Diagnostics) [28]. Briefly, 4 hrs before the invasion assay, a CIM
plate (Roche) was coated with 1:20 diluted Growth factor reduced
Matrigel basement membrane matrix (,450mg/ml) (BD Biosci-
ences). Then 40,000 cells, untransfected or transfected with empty
vector (Ev) or MAEL or PIWIL1 vectors, were seeded into each
coated well. Cell activity was followed over a time period of 72 hrs
by measuring the impedance signal in the CIM plate. The cell
activity was recorded every minute in the first 12 hrs and every
5 mins for the following 12 hrs. Then from 24 hrs onwards until
the end of the experiment, cell activity was recorded every
30 mins. In each CIM plate, triplicates of each group were
performed to obtain the mean and standard deviation. The
experiment was repeated three times.
PIWIL1 transcript sequencing
The PIWI domain of PIWIL1 transcript was PCR amplified and
products of different size were cloned into pGEM-T Easy vector
(Promega). A total of 30 positive colonies from different PCR
bands were selected from each ligation reaction and plasmid
DNAs were purified using standard alkaline lysis methods (Qiagen)
[29]. 200 ng of plasmid DNA were sequenced (Big Dye
Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems) using
SP6 and T7 universal primers.
Results
Expression of piRNA pathway genes is increased in
malignant EOC compared to benign tumors or normal
ovarian tissues
piRNA pathway genes are consistently expressed in the
mammalian ovary [11]. In order to investigate a possible role of
this pathway in EOC, we performed semi-quantitative RT-PCR
to investigate the expression of PIWIL1, PIWIL2, PIWIL3, PIWIL4
andMAEL in advanced stage serous EOC (n=25), benign ovarian
tumors (n = 19) and normal ovarian tissue (n = 8) (Table 1, Table
S3 and Fig. 1A, B). Semi quantitative analysis revealed that the
relative expression levels of PIWIL1 and MAEL were significantly
higher in malignant EOC compared to benign and normal tissues
(Fig. 2A, B). The relative expression levels of PIWIL2 and PIWIL4
in malignant groups were not significantly different to that in
benign or normal ovarian tissues (Fig. 2C, D). However, the
expression of PIWIL2 and PIWIL4 are significantly lower in
benign tumors compared to normal ovarian tissue, suggesting an
alteration of gene expression during the progression of EOC. The
relative expression of PIWIL3 is different to other PIWIL genes
such that the expression of this gene is significantly higher in the
normal ovary when compared to both malignant and benign
tissues (Fig. 2E). Furthermore, the relative expression of PIWIL3 in
normal ovary is positively correlated with patient age in the
normal ovary tissues (n = 8) (r = 0.750, P= 0.05) (Table 2). In
contrast to PIWIL3, PIWIL1 expression is negatively correlated
with the age of patients (r =20.737, P= 0.037). PIWIL1 is
expressed in growing follicles in pre-menopausal ovaries, but in
this study half of the ovaries tested were from women less than 50
years old and likely to be premenopausal.
L1 and piRNA pathway genes are over expressed in EOC
cells
To analyse the expression pattern of piRNA pathway genes and
L1 in EOC, RNA in situ hybridization was performed in malignant
EOC (n= 5) and benign ovarian tumors (n = 2) (Table 3, Fig. S1).
We found strong expression of L1 in the epithelial cells but L1 was
absent in the stromal cells in all samples (Fig. 3A, E). Also we noted
that the expression of L1 is variable in different patients (Fig. 3A).
Strong expression of PIWIL1 was found in the epithelial cells in all
EOC tissues (Fig. 3B, F) while MAEL and PIWIL2 showed strong
expression in the epithelial cells and stromal cells of all EOC
examined (Fig. 3C, G and D, H respectively).
Multiple PIWIL1 transcript variants exist in malignant EOC
PCR amplification of the PIWI domain from EOC cDNAs
produced two distinct bands compared to cDNAs from normal
Overexpression of piRNA Pathway Genes in Cancer
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testis or ovary (Fig. 4), suggesting the presence of multiple PIWIL1
transcript variants in malignant EOC. PCR products from testis
and malignant EOC were extracted, cloned and sequenced.
Multiple alignments of clone sequences showed many changes
within the PIWI domain at the nucleotide level when compared to
the testis and published PIWIL1 cDNA sequence. Single base pair
changes have been identified in PIWIL1 transcripts of malignant
EOCs (Table S2). In addition, most of these clones have exon
deletion and unspliced introns which introduce premature stop
codons. Importantly a 75-nt deletion which comprised the entire
exon 17 was found in most of the sequenced clones in 5 out of 28
EOC patients (Fig. 4B). Furthermore, some clones showed partial
splicing of introns 15 and 16 (Fig. 4B) such that 17 bp and 20 bp
from the 59 end of intron 15 and 16, respectively, are unspliced. In
order to confirm that the mutations are due to splicing, genomic
DNA of tumor samples were isolated and sequenced at the
corresponding region. No mutations were identified between
exons 15–18 (where the splicing errors occurred) in the genomic
PIWIL1 sequence (Fig. S2). In order to predict if the above post-
transcriptional alterations affect PIWIL1 function, sequences were
translated and compared to the control (testis cDNA) and
published peptide sequence (AAC97371.2). Loss of the entire
exon 17 (73-nt deletion) in 11 clones introduced a premature stop
codon in the PIWI domain (Fig. S3). Similarly, stop codons were
found in clones that have unspliced introns (not shown).
Over expression of piRNA pathway genes reduces
invasiveness in vitro
In order to investigate the possible role of piRNA pathway
genes in cancer progression, full-length PIWIL1 or MAEL
transcripts were cloned and transfected transiently into the ovarian
cancer cell line SKOV3 and assayed for invasiveness after 24 hrs
of transfection. RT-PCR was performed to validate the insertion
of plasmids into these cells. RT-PCR confirmed GFP, PIWIL1 or
MAEL over expression (Fig. S4A). Expression of MAEL and
PIWIL1 constructs remained high in the transfected cells 50 hr
post-transfection (Fig. S4A).MAEL, PIWIL1 and empty vector (Ev)
transfected cells and untransfected SKOV3 cells were applied to
the xCELLigence system to investigate their effect on cell
invasiveness [30]. Surprisingly, the invasiveness of MAEL and
PIWIL1 transfected cells was lower compared to untransfected or
empty vector cells (Fig. 5). Cell invasiveness from each group
started to reach a plateau after 30 hrs, thus only cell activity of the
first 30 hrs is shown. Our results suggest that overexpression of
PIWIL1 and MAEL have a repressive effect on SKOV3 cell
invasiveness.
Discussion
The piRNA pathway is important for TE silencing, epigenetic
regulation and stem cell self-renewal in a wide range of organisms
[31,32]. Global DNA hypomethylation and TE derepression, such
as L1, is a common feature of cancer genomes [33,34] in humans
PIWIL1 and 2 overexpression has been observed in tumors from
various tissues [15–18,21–23]. However, it is still unclear whether
piRNA pathway genes are differentially expressed in ovarian
cancer or have a role in ovarian tumor progression. We examined
the expression of piRNA pathway genes PIWIL1–4,MAEL and L1
in malignant EOC, benign tumors and normal ovary tissues, and
also investigated possible roles of PIWIL1 and MAEL in ovarian
cancer cell lines.
Expression of PIWIL1–2 has been investigated in various
cancerous tissues [15–18,21,23,35], but not MAEL, PIWIL3 and
PIWIL4. Although the expression of PIWIL2 and 4 appeared high
in tumor samples this was not significant, likely due to the fact that
PIWIL2 and PIWIL4 were strongly expressed in normal ovarian
tissues (Fig. 1B) and their expression among malignant tissues is
highly variable. The expression of PIWIL1 and MAEL however is
significantly increased in malignant EOC when compared to
benign tumors. PIWIL1 and MAEL, but not PIWIL2 and 4, were
significantly up regulated when compared to normal ovaries. In
contrast to PIWIL2 and 4 that are expressed in all normal ovarian
tissues examined, the expression of PIWIL1 and MAEL is found
only in a subset of normal ovarian tissues from patients who were
less than 50 years old. In normal ovary, PIWIL1 and MAEL are
expressed in the cumulus cells of growing follicles in human [11].
The normal ovarian tissues tested are from individuals aged 44–76
years old, and half of these samples were derived from individuals
less than 50 years old. Thus, the variable expression of PIWIL1
and MAEL in the normal ovaries could be explained by the
difference in abundance of growing follicles, which express piRNA
pathway genes across the samples.
Figure 1. piRNA pathway gene expression in human normal ovaries and ovarian cancers. RT-PCR analyses of PIWIL1-4 and MAEL
expression in (A) malignant EOC, benign ovarian cancers (B) normal ovaries and (C) ovarian cancer cell lines. This is a representation of 4 out of 25
malignant EOC and 19 benign ovarian cancer tissues. Increased expression of PIWIL1, 2, 4 and MAEL, but not PIWIL3, are found in malignant cancers
compared to benign tumors. All normal ovaries show PIWIL2 and PIWIL4 expression but only some have PIWIL1, 3 and MAEL expression. No
endogenous PIWIL1, 2, 4 and MAEL expression is detected in OVCAR3 and SKOV3 cells. Ova* indicates tissue from a 20-year old pre-menopausal ovary
while other ovaries are from individuals aged 44–76 years old.
doi:10.1371/journal.pone.0099687.g001
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MAEL is known as a cancer/testis gene as it is expressed in testis
and a number of cancer cell lines [36]. Here we identified for the
first time the increased expression of MAEL in malignant EOC
and benign ovarian tumors. Similar to PIWI, MAEL is essential to
ensure proper germline stem cell differentiation in Drosophila and
other vertebrates [37]. Overexpression of piRNA pathway genes
in EOC may indicate that some stem cell characteristics are
present in tumor cells or that the piRNA pathway has been
activated for example by activity of retrotransposons. Expression
of these genes may also be a signature of the presence of ovarian
cancer stem cells [38].
Figure 2. Box plot representing the expression of piRNA pathway genes in malignant EOC, benign ovarian cancer tissues and
normal ovaries. Semi-quantitative RT-PCR analysis of mRNA expression (relative to ACTB) of (A) PIWIL1, (B) MAEL, (C) PIWIL2, (D) PIWIL4 and (E)
PIWIL3. (F) P-value of each comparison group. Malignant EOC (n = 25), benign ovarian cancer tissues (n = 19) and normal ovaries (n = 8). Kruskal-Wallis
Test was performed to compare the gene expression level between two groups. Filled dot indicates mean of each group. * indicates 0.001,P,0.05;
*** indicates P,0.001; NS, not significant.
doi:10.1371/journal.pone.0099687.g002
Overexpression of piRNA Pathway Genes in Cancer
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The expression of piRNA pathway genes in normal ovary and
certain types of EOC may provide a new perspective on the origin
of ovarian cancer. Somatic cells of the maturing follicle may come
in contact with the ovarian surface epithelium during ovulation or
may be present in the inclusion cyst which is thought to play a role
in the origin of epithelial ovarian cancer [3] although the presence
of inclusion cysts seems to not per se increase the risk of developing
ovarian cancer [39]. Hypomethylation of the L1 promoter region
is correlated with increased L1 mRNA expression, in malignant
breast cancer tissues and cell lines [40,41]. The expression of
PIWIL genes and MAEL in both normal ovary and malignant
EOC correlate with increased expression of repeat elements and
raises the possibility that the piRNA pathway may have been
triggered by TE expression. However, we noticed that L1
expression was absent in earlier stage malignant tumors (n = 6)
but consistently present at all stage 3c tumor samples. This
provides some circumstantial evidence that the activation of
piRNA pathway genes may precede L1 expression during tumor
progression. This is consistent with work in other tumors that
correlate L1 expression with cancer progression [42]. Maelstrom
knock out results in decreased DNA methylation in gonads, but
not in somatic tissue. In gonads this leads to a dramatic increase in
Table 2. Correlation between age of patients and piRNA pathway gene expression.
Genes R-value (M, n =25) P-value (M, n =25) R-value (B, n=19) P-value (B, n=19) R-value (N, n =8) P-value (B, n=19)
PIWIL1 20.376 0.064 20.194 0.426 20.737 0.037*
PIWIL2 20.080 0.702 20.442 0.058 0.491 0.217
PIWIL3 20.082 0.695 0.595 0.009* 0.75 0.05
PIWIL4 20.249 0.231 20.376 0.113 0 1.0
MAEL 20.087 0.678 0.251 0.457 20.220 0.601
Spearman’s correlation test; M = malignant; B = benign; N = normal; negative value = negative correlation; positive value = positive correlation; P ,0.05 and
* indicates the correlation between the age of patients and piRNA pathway gene expression is significant. The R-value closer to 6 1 indicates the stronger correlation.
doi:10.1371/journal.pone.0099687.t002
Figure 3. L1, PIWIL1, MAEL and PIWIL2 are expressed in the epithelial cells of malignant EOC. In situ analysis of (A, A’, E) L1, (B, B’, F) PIWIL1,
(C, C’, G) MAEL, (D, D’, H) PIWIL2 in two malignant EOC (A-D from SC3 while E-H from SC2). (A’-D’) Amplification images of A-D respectively. Strong
expression of piRNA pathway genes and L1 was found in the squamous-to-cuboidal like epithelial cells of both malignant EOC except PIWIL1 which
only expressed in SC2 but not SC3. L1 has patchy expression in some EOC such that some epithelial cells seem to have stronger L1 expression
compared to others.MAEL and PIWIL2 but not PIWIL1 are also expressed in the stromal cells in both EOC. (E’-H’) Negative controls with sense probe of
L1, PIWIL1, MAEL and PIWIL2 respectively. Ep = epithelial cells; S = stromal cells. Scale bar = 50mm.
doi:10.1371/journal.pone.0099687.g003
Overexpression of piRNA Pathway Genes in Cancer
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transposable element expression in the germ cells [43]. Our
observation of MAEL overexpression in the absence of detectable
L1 expression in early stage tumor samples raises the possibility
that non-functional MAEL may play a role in decreasing DNA
methylation promoting subsequent L1 expression.
Although PIWIL1 transcript level was significantly increased in
malignant EOC compared to benign and normal tissues, cloning
and sequencing of these transcripts suggested that these transcripts
may produce aberrant and non-functional PIWIL1 protein.
Multiple mutations were found in PIWIL1 transcripts including
unspliced introns, loss of exons as well as single base pair changes.
Single base pair changes maybe a result of RNA editing [44].
Among thirty clones of PIWIL1 transcripts from malignant tissues,
one third of these clones have A to G (I) substitution. In addition,
most of these clones have exon deletion and unspliced introns
which introduced premature stop codons (Table 2). The presence
of premature stop codons suggests that although PIWIL1
expression is high in malignant tissues, the corresponding protein
(if any) maybe truncated and non-functional. Such defects in pre-
mRNA splicing have been found in liver cancer and have been
implicated in its progression [45].
In situ analyses revealed that L1, PIWIL1, PIWIL2 and MAEL
are strongly expressed in the epithelial cells. Surprisingly we also
found evidence for PIWIL2 and MAEL expression in the stromal
cells in malignant EOC. It is unclear at this point if these are
epithelial cells invading stromal tissue or individual stromal cells
expressing these genes. Several lines of evidence have demon-
strated that alteration of gene expression in stromal cells may
create a microenvironment which facilitates tumor growth, playing
a role in cancer progression [46–48]. For example, changes of
gene expression in the stromal cells surrounding colon cancer cells
have been shown to produce matrix metalloproteinases (MMPs)
which increase tumor invasion capacity in vitro and in vivo [47,49].
There are a number of ways in which genes associated with the
piRNA pathway can play a role in genome regulation and it has
been suggested that activity of these genes can have effects on
methylation and expression of TEs as well as genome instability. In
addition, PIWI proteins can mediate, activating or repressing
effects on chromatin via interaction with heterochromatin protein
1 or polycomb group proteins. Despite this experimental evidence
elucidating the role of PIWIL1 and MAEL in cancer is difficult as
differing effects are observed. Recent studies suggest that PIWIL1
maybe a marker for cancer cell proliferation as it is co-expressed
Table 3. Expression trends of piRNA pathway genes and L1 in the EOC after in situ hybridisation.
Patient Gene Epithelial cells Stromal cells
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Figure 4. PIWIL1 transcript variants in EOC. (A) PIWIL1 expression in control tissues (human testis, normal ovary (ov) 1, 2) and EOC tissue SC1 and 2.
In the positive control, a 500 bp band was amplified, but in malignant SC1, two bands were obtained. (B) cDNAmultiple alignment (partial) showing that
most of the clones have a deletion of exon 17 (DD3) and 3 clones have partial splicing of intron 15 and 16 (;1,;2). PIWIL1_ccds: published cDNA of
PIWIL1 (CCDS9268); Testis C1: testis transcript clone 1; B1–3, B6, B9–B14, C6, C8, C9, C10–C15, D1–D10: clones with PIWIL1 transcripts.
doi:10.1371/journal.pone.0099687.g004
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with KI67 [16], a reliable proliferating cell marker [50]. In
addition, studies in a Drosophila brain tumor model suggested that
inactivation of Piwi suppressed tumor growth and thus Piwi may
promote cancer progression in this system [51]. This is further
supported by slowed tumor growth after knockdown of PIWIL1 in
lung cancer cell lines [52]. Recently several other studies
investigated the effect of PIWI and MAEL overexpression on
tumor progression. Liu et al observed increased expression of the
Maelstrom gene in hepatocellular cancer (HCC). When overex-
pressed, MAEL led to increased growth, migration and invasive-
ness in HCC cell lines [53]. Liang et al. showed in another study,
that stable overexpression of Piwil2 in mouse embryonic fibroblasts
increased proliferation and invasiveness [54]. However, in humans
over expression of PIWIL1 did not increase cell growth but caused
programmed cell death in myeloid leukaemia KG1 cells,
suggesting that PIWIL1 may prevent tumor development in these
cells [55]. Our results in SKOV3 cells support those findings.
Together this suggests that MAEL may undergo different roles
depending on cell type and differentiation status. Given that these
results were obtained in different cell types and tested in different
assays and species it is difficult to reconcile the divergent results.
One possible pathway that may shed some light on this is the
AKT-GSK3b-Snail pathway. Recent work showed that MAEL
overexpression triggers EMT via the AKT-GSK3b-SNAIL
pathway. It has been suggested that activation of AKT will lead
to degradation of SNAIL ultimately leading to EMT and increased
invasiveness. However in SKOV3 cells SNAIL overexpression has
been reported to increase invasiveness [56]. The decrease of
invasiveness after MAEL overexpression observed in the present
study could be due to a reduction in SNAIL activity by MAEL.
Conclusions
Increasing evidence of piRNA pathway activity in various
cancers raises questions about a role of this pathway in the origin
and progression of these malignancies. As reported in this study,
over expression of piRNA pathway genes and L1 elements in
malignant ovarian cancer suggest a role of this pathway in EOC.
Expression of PIWIL1 and MAEL is significantly up regulated in
malignant EOC when compared to benign lesions and normal
ovaries. In situ analyses revealed that L1, PIWIL1, PIWIL2 and
MAEL are strongly expressed in the cancerous cells but
surprisingly MAEL and PIWIL2 expression was also found in the
stromal cells lining tumor tissues, suggesting a change in cell
composition or identity in the tissue surrounding the cancer cells.
Identification of aberrant PIWIL1 transcript revealed that non-
functional PIWIL1 proteins may be produced. In contrast to other
cell systems, in vitro real-time invasion assay showed that over
expression of piRNA pathway components such as PIWIL1 and
MAEL has a repressive effect on ovarian cancer cell invasiveness.
Together, these results highlight the complexity in which the
piRNA pathway may influence tumor progression and warrant
further work to better understand the role of the piRNA pathway
in the origin and progression of ovarian cancer.
Supporting Information
Figure S1 Expression of piRNA pathway genes and L1 in
malignant EOC. (A) MAEL antisense from SC2 which shows
strong expression in stromal cells (+++) compared to epithelial cells
which have weak expression. (B) L1 expression in SC3. Epithelial
cells have patchy strong expression of L1 while low expression was
observed in the stromal cells. +++ strong expression; + weak
expression. (A’–B’) Negative controls with a sense probe of MAEL
and L1 respectively. Scale bar = 50mm
(TIF)
Figure S2 No mutations found in the genomic PIWIL1
sequence in serous carcinoma 1. SC1 gDNA was aligned
with published PIWIL1 gDNA (ENSG00000125207) sequence
from exon 15 to exon 18. All exon sequences and partial intron
Figure 5. Invasion assay of MAEL or PIWIL1 transfected SKOV3 cells. PIWIL1 and MAEL transfected cells have lower invasiveness compared to
untransfected cells and Ev transfected cells. In each experiment, each group was performed in triplicate and this experiment was repeated three
times. This is a combined data plot of three independent experiments for all groups. Error bars represent standard deviation. WT indicates
untransfected SKOV3 cells; empty vector (Ev), MAEL and PIWIL1 indicate cells transfected with MAEL or PIWIL1 vectors. None indicates well without
cells.
doi:10.1371/journal.pone.0099687.g005
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sequences were shown. Green bar indicates 100% conservation
between the aligned sequences.
(TIF)
Figure S3 PIWIL1 transcript variants encoded prema-
ture stop codon. (A) 19 clones with exon 17 (DD13) deletions, 3
clones with unspliced introns and 1 clone with a single base change
resulted in the introduction of premature stop codons. PI-
WIL1_ccds9268: published PIWIL1 peptide sequence
(AAC97371.2); Testis C1: translated testis clone 1; B1-3, B6, B9-
B14, C6, C8, C9, C10-C15, D1-D10: clones with PIWIL1
translated sequence. * inside the boxes in panel A indicates
premature stop codon.
(TIF)
Figure S4 Expression of PIWIL1 and MAEL is main-
tained in transfected cells throughout the invasion
study. (A) RT-PCR showing the expression of GFP, MAEL and
PIWIL1 in transfected cells (left panel) at the start of invasion study
(24 hrs post-transfection) and (right panel) the end of invasion
study (74 hrs after transfection). The expression of GFP, MAEL or
PIWIL1 can only be detected in specific vector transfected cells but
not empty vector transfected or wildtype cells. (B) A high number
of GFP positive cells were still observed after 74 hrs of transfection.
Scale bar = 10mm.
(TIF)
Table S1 Primers for RT-PCR and in situ hybridization
(ISH).
(DOCX)
Table S2 Nucleotide changes in PIWI domain of PIWIL1
transcripts.
(DOCX)
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